The maker of EpiPen has agreed to pay the government $465 million after overcharging for the medicine

Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it overcharged government healthcare agencies for the medicine, according to a release from the firm.

Mylan had underpaid Medicare and Medicaid by classifying the EpiPen as a generic drug. Generic drugs are subject to a 13% rebate from the marker to Medicaid and Medicare, rather than a 23.1% rebate for brand name drugs.

Following the news, shares of Mylan had jumped nearly 8% in after-hours trading to $38.75 per share.

More to come…

NOW WATCH: FEMA is tracking Hurricane Matthew using the ‘Waffle House Index’

NOW WATCH: Money & Markets videos

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.